AstraZeneca (AZN) will pay China's Dizal Jiangsu Pharmaceutical $600M upfront for global rights to a lung cancer drug, strengthening its oncology portfolio with a commercial-stage treatment.
The drugmaker has entered into an exclusive license deal with Dizal for Zegfrovy (sunvozertinib), a novel